We are live on
!
Find out more
CANY
Caxton Associates (New York) Portfolio holdings
AUM
$3.18B
1-Year Est. Return
54.49%
This Fund
S&P 500
This Quarter
Est. Return
+26.3%
1 Year Est. Return
+54.49%
3 Year Est. Return
+73.91%
5 Year Est. Return
+212.89%
10 Year Est. Return
+632.2%
AUM
$1.15B
AUM Growth
+$601M
(+111%)
Cap. Flow
+$483M
Cap. Flow
% of AUM
42.15%
Top 10 Holdings %
Top 10 Hldgs %
60.26%
Holding
693
New
300
Increased
46
Reduced
89
Closed
249
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SPDR Gold Trust
GLD
|
+$403M |
| 2 |
HES
Hess
HES
|
+$46.3M |
| 3 |
iShares Silver Trust
SLV
|
+$26M |
| 4 |
Amazon
AMZN
|
+$20.5M |
| 5 |
iShares JPMorgan USD Emerging Markets Bond ETF
EMB
|
+$16M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$82.8M |
| 2 |
JPMorgan Chase
JPM
|
+$54.1M |
| 3 |
Alibaba
BABA
|
+$51.1M |
| 4 |
Deere & Co
DE
|
+$31.8M |
| 5 |
JD.com
JD
|
+$14.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 14% |
| 2 | Energy | 7.45% |
| 3 | Consumer Discretionary | 7.05% |
| 4 | Utilities | 4.19% |
| 5 | Healthcare | 3.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Steven Madden
SHOO
$3.55B
| $535K | 0.05% |
+21,655
| New | +$507K |
|
127
Teladoc Health
TDOC
$1.3B
| $535K | 0.05% |
2,803
-17,772
| -86% | -$3.11M |
|
128
Universal Health Services
UHS
$10.5B
| $532K | 0.05% |
+5,732
| New | +$573K |
|
129
Cboe Global Markets
CBOE
$29.9B
| $531K | 0.05% |
5,691
-1,524
| -21% | -$150K |
|
130
Progress Software
PRGS
$1.76B
| $523K | 0.05% |
+13,485
| New | +$514K |
|
131
Corbus Pharmaceuticals
CRBP
$190M
| $521K | 0.05% |
2,070
+1,371
| +196% | +$277K |
|
132
Shutterstock
SSTK
$219M
| $518K | 0.05% |
+14,823
| New | +$534K |
|
133
Globe Life
GL
$14.3B
| $517K | 0.05% |
6,959
+3,912
| +128% | +$297K |
|
134
Fortinet
FTNT
$117B
| $512K | 0.04% |
+18,640
| New | +$468K |
|
135
Emergent Biosolutions
EBS
$248M
| $509K | 0.04% |
+6,434
| New | +$479K |
|
136
Equity Residential
EQR
$25.1B
| $509K | 0.04% |
8,655
-9,019
| -51% | -$559K |
|
137
Alnylam Pharmaceuticals
ALNY
$29.3B
| $508K | 0.04% |
+3,431
| New | +$463K |
|
138
KLA
KLAC
$259B
| $506K | 0.04% |
+26,030
| New | +$445K |
|
|
STMP
139
DELISTED
Stamps.com, Inc.
STMP
| $503K | 0.04% |
2,737
-763
| -22% | -$131K |
|
140
ResMed
RMD
$30.7B
| $498K | 0.04% |
2,596
-3,865
| -60% | -$632K |
|
|
AMED
141
DELISTED
Amedisys
AMED
| $497K | 0.04% |
2,501
+313
| +14% | +$58.4K |
|
142
Voya Financial
VOYA
$9.19B
| $497K | 0.04% |
+10,662
| New | +$473K |
|
143
Wingstop
WING
$3.18B
| $494K | 0.04% |
+3,554
| New | +$414K |
|
|
IPHI
144
DELISTED
INPHI CORPORATION
IPHI
| $492K | 0.04% |
+4,189
| New | +$441K |
|
|
CPRX
145
DELISTED
Catalyst Pharmaceutical
CPRX
| $488K | 0.04% |
105,702
+79,622
| +305% | +$358K |
|
146
Sarepta Therapeutics
SRPT
$1.77B
| $484K | 0.04% |
+3,020
| New | +$411K |
|
147
Lincoln National
LNC
$8.81B
| $483K | 0.04% |
13,134
-4,995
| -28% | -$176K |
|
148
Gilead Sciences
GILD
$165B
| $481K | 0.04% |
+6,247
| New | +$479K |
|
|
QVCGA
149
DELISTED
QVC Group Inc Series A
QVCGA
| $481K | 0.04% |
+1,042
| New | +$407K |
|
150
Cirrus Logic
CRUS
$6.26B
| $480K | 0.04% |
+7,773
| New | +$531K |
|
Similar funds
BFM
MWM
CCM
ECG
LSAG
KL
WP
RDIA
Caxton Associates (New York)'s Q2 2020 Portfolio in Review
As of Q2 2020, Caxton Associates (New York) held 693 positions worth $1.15B, up 111% from $544M the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Caxton Associates (New York) deployed $483M of net new capital in Q2 2020, opening 300 new positions and adding to 46 existing holdings. Its largest new stake was Hess: 1,011,414 shares worth $52.4M.
By sector, the portfolio is most concentrated in Technology at 14% of assets, down from 27% a quarter earlier, followed by Energy and Consumer Discretionary.
On the sell side, the largest reduction was JPMorgan Chase, an estimated $54.1M trimmed.
- Caxton Associates (New York)'s largest Q2 2020 buy was Hess: 1,011,414 shares worth $52.4M.
- Caxton Associates (New York) added most to SPDR Gold Trust in Q2 2020, an estimated $403M increase.
- Caxton Associates (New York)'s biggest Q2 2020 reduction was JPMorgan Chase, cutting an estimated $54.1M.
- Caxton Associates (New York) fully exited Microsoft in Q2 2020, selling an estimated $82.8M.
- Caxton Associates (New York)'s ten largest holdings make up 60% of its $1.15B portfolio in Q2 2020.
- Caxton Associates (New York) opened 300 new positions and closed 249 in Q2 2020.
- Caxton Associates (New York)'s portfolio value rose 111% quarter-over-quarter to $1.15B.
Based on Caxton Associates (New York)'s 13F filing for Q2 2020, filed 14 Aug 2020.